Eikon Therapeutics releases Q2 2026 company update on clinical programs
Eikon Therapeutics issued a quarterly update covering its drug development strategy and platform progress. The filing contains forward-looking statements regarding clinical trials, technology applications, and 2026 milestones for the biotech company.
View filing at SEC.gov →